The first in class angiotensin receptor neprilysin inhibitor , LCZ696 has been shown to reduce levels of N-terminal pro-brain natriuretic peptide ( NT-proBNP ) , reduce left atrial size and improve New York Heart Association ( NYHA ) class in patients with heart failure with preserved ejection fraction ( HFpEF ) .